Supernus Pharmaceuticals Stock Investor Sentiment
| SUPN Stock | USD 36.57 0.42 1.14% |
About 55% of Supernus Pharmaceuticals' investor base is interested to short. The analysis of overall sentiment of trading Supernus Pharmaceuticals stock suggests that many investors are impartial at this time. Supernus Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Supernus Pharmaceuticals. Many technical investors use Supernus Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Panic Vs Confidence
45
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Supernus Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Supernus Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Supernus Historical Sentiment
Although Supernus Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Supernus, such as negative comments on social media and news outlets, may cause fear in the market and push Supernus Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Supernus.
Supernus |
Supernus Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Supernus Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Supernus Pharmaceuticals Historical Investor Sentiment
Investor biases related to Supernus Pharmaceuticals' public news can be used to forecast risks associated with an investment in Supernus. The trend in average sentiment can be used to explain how an investor holding Supernus can time the market purely based on public headlines and social activities around Supernus Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Supernus Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Supernus Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Supernus Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Supernus Pharmaceuticals.
Far too much social signal, news, headlines, and media speculation about Supernus Pharmaceuticals that are available to investors today. That information is available publicly through Supernus media outlets and privately through word of mouth or via Supernus internal channels. However, regardless of the origin, that massive amount of Supernus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Supernus Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Supernus Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Supernus Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Supernus Pharmaceuticals alpha.
Supernus Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 10000 shares by Gemayel Georges of Supernus Pharmaceuticals at 31.33 subject to Rule 16b-3 | 09/13/2024 |
2 | Acquisition by Hudson Frederick M. of 5369 shares of Supernus Pharmaceuticals subject to Rule 16b-3 | 09/16/2024 |
3 | Acquisition by Padmanabh Bhatt of 20000 shares of Supernus Pharmaceuticals at 27.94 subject to Rule 16b-3 | 10/21/2024 |
4 | Supernus Reports Q3 Earnings What Key Metrics Have to Say | 11/05/2024 |
5 | Supernus Pharmaceuticals Third Quarter 2024 Earnings Beats Expectations | 11/06/2024 |
6 | Disposition of 125000 shares by Jack Khattar of Supernus Pharmaceuticals at 9.13 subject to Rule 16b-3 | 11/07/2024 |
7 | Supernus Pharmaceuticals director sells shares worth 520,480 | 11/08/2024 |
8 | Disposition of 20000 shares by Newhall Charles W Iii of Supernus Pharmaceuticals at 9.13 subject to Rule 16b-3 | 11/11/2024 |
9 | Supernus Pharmaceuticals Recently Launched Qelbree Is Powering Growth - Seeking Alpha | 11/12/2024 |
10 | Supernus Pharmaceuticals Inc Shares Gap Down to 36.57 on Nov 14 | 11/14/2024 |
11 | ARMISTICE CAPITAL, LLC Acquires Significant Stake in Rockwell Medical Inc | 11/15/2024 |
12 | Supernus Pharmaceuticals Reaches 80-Plus Relative Strength Rating Benchmark - Inkl | 11/21/2024 |
13 | Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference | 11/26/2024 |
Check out Supernus Pharmaceuticals Hype Analysis, Supernus Pharmaceuticals Correlation and Supernus Pharmaceuticals Performance. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share 11.877 | Quarterly Revenue Growth 0.142 | Return On Assets 0.0289 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.